FNY Investment Advisers LLC Raises Stake in Zimmer Biomet Holdings, Inc. $ZBH

FNY Investment Advisers LLC raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 72.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 690 shares of the medical equipment provider’s stock after purchasing an additional 290 shares during the quarter. FNY Investment Advisers LLC’s holdings in Zimmer Biomet were worth $62,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Washington Trust Advisors Inc. acquired a new position in Zimmer Biomet in the 1st quarter valued at about $30,000. Columbia River Financial Group LLC purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at approximately $30,000. Accent Capital Management LLC acquired a new position in shares of Zimmer Biomet in the first quarter valued at approximately $35,000. Cullen Frost Bankers Inc. raised its stake in shares of Zimmer Biomet by 1,452.4% during the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 305 shares during the last quarter. Finally, Hilltop National Bank acquired a new stake in shares of Zimmer Biomet during the second quarter worth $42,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.8%

Shares of Zimmer Biomet stock opened at $103.13 on Friday. The company has a 50-day moving average of $101.86 and a two-hundred day moving average of $97.71. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The stock has a market cap of $20.43 billion, a PE ratio of 25.09, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the previous year, the company earned $2.01 EPS. The company’s quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is 23.36%.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of analyst reports. UBS Group upped their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Rothschild & Co Redburn began coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They set a “buy” rating and a $130.00 price target on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. BTIG Research lifted their price objective on Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a report on Monday, October 13th. Finally, Raymond James Financial increased their target price on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $111.94.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.